Brussels, Belgium, June 16, 2016
Merodis, a corporate finance consulting firm part of the EuroMerger network, is pleased to disclose that it has assisted KiOmed Pharma for its latest capital increase totalling EUR 6,1m.
KiOmed Pharma is a spin-off from KitoZyme and Liège University (Belgium) developing, producing and marketing ultrapure vegetable-based chitosan and derivatives for high-end medical applications.
Through a series of comparative and pre-clinical studies, KiOmed Pharma has repeatedly demonstrated that its chitosan, a non-cross-linked biocompatible formulation, offers by its design promising additional and tuneable attributes in comparison with hyaluronic acid, whose market is expected to reach EUR 10bn by 2019.
For more information, please contact:
email@example.com, +32 495 58 68 98
Gabriel de Launoit
firstname.lastname@example.org , +32 487 71 63 01